A Strategic Partnership Shaping the Future of Regenerative Cardiac Medicine
07/04/2025
With the signing of an equity agreement on April 2, 2025, biotech pioneers Repairon GmbH and life science investor Bioventure Management GmbH, both based in Göttingen, have entered into a strategic partnership with the potential to fundamentally change the treatment of heart failure worldwide. Bioventure is investing in Repairon – a spin-off from the University Medical Center Göttingen (UMG) – with the aim of supporting the clinical development and commercialization of its pioneering “heart patch” therapy.
“With Repairon, we are investing in a company that not only possesses groundbreaking technology, but also exemplifies how medical progress can be translated into societal benefit through visionary research and entrepreneurial excellence,”says Dr. Erik Hoppe, Managing Director of Bioventure. “We believe that Repairon’s regenerative therapies will play a key role in the cardiology of tomorrow.”
Contact:
Bioventure Management GmbH
Dr. Erik Hoppe
info@bioventure.de
www.bioventure.de
+49 (551) 48 97 34 50
Repairon GmbH
Dr. Lothar Germeroth
info@repairon.de
www.repairon.de
+49 (551) 2887 8480
